Randomized placebo-controlled clinical trial on the efficacy of a mouthrinse containing CHX and CPC on the intraoral viral load and infectivity in SARS-CoV-2 positive patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00027812

Enrollment

Registered

2022-01-12

Start date

2022-01-13

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1

Interventions

Group 1: Verum (Perio-Aid Active Control, Dentaid, Barcelona, Spain)

60s mouthrinse using 20mL Group 2: Placebo (0.9% NaCl): 60s mouthrinse using 20mL

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a positive test for SARS-CoV- 2 and onset of symptoms within the last 72 hrs as well as a positive antigen point-of-care test

Exclusion criteria

Exclusion criteria: - Indication for intubation or mechanical ventilation - severe stomatitis

Design outcomes

Primary

Measure	Time frame
Reduction of intraoral SARS-CoV-2 viral load (detection of viral load immediately before and 30 min after rinsing with a commercially available mouth rinse containing chlorhexidine and cetylpyridinium chloride (Perio-Aid Active Control, Dentaid, Barcelona, Spain) by RT-PCR compared with placebo control).	—

Secondary

Measure	Time frame
Reduction of intraoral SARS-CoV-2 infectivity (viral culture and ELISA tests immediately before and 30 min after rinsing with a commercially available mouthwash containing chlorhexidine and cetylpyridinium chloride (Perio-Aid Active Control, Dentaid, Barcelona, Spain) compared with placebo control).	—

Countries

Germany

Contacts

Public ContactFabian Cieplik

Poliklinik für Zahnerhaltung und Parodontologie, Universitätsklinikum Regensburg

fabian.cieplik@ukr.de09419446024

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 9, 2026